12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Seliciclib: Interim Phase I data

Interim data from 11 evaluable patients with advanced solid tumors in an open-label, U.S. Phase I trial showed that sequential administration of oral sapacitabine and oral seliciclib led to 2 partial responses (1 patient with pancreatic cancer and 1 patient with breast...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >